BRCA2 and cancer: In a recent statement of the International Cancer of the Pancreas Screening (CAPS) Consortium, most members felt that BRCA2 mutation carriers with ≥ 1 affected first-degree relative, or with two affected relatives (whether or not first degree), should be considered candidates for screening (Canto et al., 2013).